Literature DB >> 24276813

Statin therapy for primary prevention of cardiovascular disease.

Fiona C Taylor1, Mark Huffman, Shah Ebrahim.   

Abstract

CLINICAL QUESTION: Do statins reduce rates of cardiovascular events when used for primary prevention? BOTTOM LINE: When used for primary prevention, statins are associated with lower rates of all-cause mortality, major vascular events, and revascularizations compared with placebo. Statin therapy is not associated with increased rates of life-threatening adverse effects such as cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24276813     DOI： 10.1001/jama.2013.281348

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


  39 in total

1.  Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness.

Authors:  Saad B Omer; Varun K Phadke; Robert A Bednarczyk; Allison T Chamberlain; Jennifer L Brosseau; Walter A Orenstein
Journal:  J Infect Dis       Date:  2015-10-28       Impact factor: 5.226

2.  Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Joseph Yeboah; Stefan Sillau; Joseph C Delaney; Michael J Blaha; Erin D Michos; Rebekah Young; Waqas T Qureshi; Robyn McClelland; Gregory L Burke; Bruce M Psaty; David M Herrington
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

3.  On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate.

Authors:  Alejandro Macchia; Javier Mariani; Marilena Romero; Fabio Robusto; Vito Lepore; Antonio Dettorre; Gianni Tognoni
Journal:  Eur J Clin Pharmacol       Date:  2015-02-11       Impact factor: 2.953

4.  Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.

Authors:  Martin Bødtker Mortensen; Erling Falk; Dong Li; Khurram Nasir; Michael J Blaha; Veit Sandfort; Carlos Jose Rodriguez; Pamela Ouyang; Matthew Budoff
Journal:  JACC Cardiovasc Imaging       Date:  2017-07-25

5.  Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

Authors:  Young K Chen; Tiziana Bonaldi; Alessandro Cuomo; Joselyn R Del Rosario; David J Hosfield; Toufike Kanouni; Shih-Chu Kao; Chon Lai; Neethan A Lobo; Jennifer Matuszkiewicz; Andrew McGeehan; Shawn M O'Connell; Lihong Shi; Jeffrey A Stafford; Ryan K Stansfield; James M Veal; Michael S Weiss; Natalie Y Yuen; Michael B Wallace
Journal:  ACS Med Chem Lett       Date:  2017-07-27       Impact factor: 4.345

6.  The lipidome in major depressive disorder: Shared genetic influence for ether-phosphatidylcholines, a plasma-based phenotype related to inflammation, and disease risk.

Authors:  E E M Knowles; K Huynh; P J Meikle; H H H Göring; R L Olvera; S R Mathias; R Duggirala; L Almasy; J Blangero; J E Curran; D C Glahn
Journal:  Eur Psychiatry       Date:  2017-02-21       Impact factor: 5.361

7.  PGC-1α plays a pivotal role in simvastatin-induced exercise impairment in mice.

Authors:  Miljenko Valentin Panajatovic; François Singh; Noëmi Johanna Roos; Urs Duthaler; Christoph Handschin; Stephan Krähenbühl; Jamal Bouitbir
Journal:  Acta Physiol (Oxf)       Date:  2019-11-04       Impact factor: 6.311

Review 8.  Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms.

Authors:  Amirhossein Sahebkar; Paolo Di Giosia; Cosimo Andrea Stamerra; Davide Grassi; Claudio Pedone; Gianna Ferretti; Tiziana Bacchetti; Claudio Ferri; Paolo Giorgini
Journal:  Br J Clin Pharmacol       Date:  2016-04-03       Impact factor: 4.335

Review 9.  Characterization of coronary atherosclerosis by intravascular imaging modalities.

Authors:  Satoshi Honda; Yu Kataoka; Tomoaki Kanaya; Teruo Noguchi; Hisao Ogawa; Satoshi Yasuda
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

Review 10.  A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.

Authors:  Philip A Ades
Journal:  Coron Artery Dis       Date:  2014-06       Impact factor: 1.439
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.